Overview
Boston Scientific's neuromodulation portfolio spans spinal cord stimulation, deep brain stimulation, and sacral neuromodulation for pain, movement disorders, and pelvic conditions. Their Vercise Genus DBS system and WaveWriter Alpha SCS platform represent the company's latest advances in closed-loop, personalized neural therapy.
More in Neuromodulation
Latest industry news
It's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments
2026-06-23 · Product
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
2026-06-13 · Research
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
2026-06-11 · Product
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
2026-06-09 · Industry
Company details
Category
⚡ Neuromodulation
Location
Marlborough, MA, USA
Funding
NYSE: BSX
Listed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →